Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
10.04
-0.62 (-5.82%)
Nov 21, 2024, 2:07 PM EST - Market open
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
233.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | - | - | - |
Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBNTC News
- 6 days ago - Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 17 days ago - Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Benitec Biopharma: OPMD Program Continues To Advance With Catalysts - Seeking Alpha
- 5 weeks ago - Benitec Biopharma Announces Updated Investor Webcast Information - GlobeNewsWire
- 5 weeks ago - Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society - GlobeNewsWire
- 7 weeks ago - Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 months ago - Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society - GlobeNewsWire
- 4 months ago - Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study - GlobeNewsWire